Innovassynth Technologies (India) Ltd
Incorporated in 2008, Innovassynth Technologies Ltd is a Contract Research, Development and Manufacturing Organization (CRDMO) specializing in pharmaceutical intermediates, oligonucleotide building blocks and specialty chemicals.
- Market Cap ₹ 1,299 Cr.
- Current Price ₹ 140
- High / Low ₹ 140 / 45.0
- Stock P/E
- Book Value ₹ 10.2
- Dividend Yield 0.00 %
- ROCE -24.9 %
- ROE -40.6 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 1.34% over last quarter.
Cons
- Stock is trading at 13.8 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -20.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 102 | 146 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 127 | 140 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -24 | 6 |
| OPM % | 22% | -24% | 4.2% | ||||||||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 8 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 |
| Profit before tax | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -40 | -10 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -28% | |
| -0 | -0 | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -29 | -3 | |
| EPS in Rs | -0.08 | -0.11 | -0.11 | -0.13 | -0.18 | -0.18 | -0.17 | -0.22 | -0.22 | -0.23 | -0.33 | -3.10 | -2.97 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 135% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 74% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 61% |
| 3 Years: | 85% |
| 1 Year: | 54% |
| Return on Equity | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -15% |
| 3 Years: | -21% |
| Last Year: | -41% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 28 | 75 |
| Reserves | -1 | -1 | -2 | -2 | -4 | -4 | -4 | 11 | 10 | 9 | 15 | 19 |
| 0 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 113 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 71 | |
| Total Liabilities | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 278 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 130 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Investments | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 2 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 143 | |
| Total Assets | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 278 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -39 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9 | |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 29 | |
| Net Cash Flow | -0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | 0 | -19 |
| Free Cash Flow | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -45 |
| CFO/OP | 95% | 85% | 73% | 48% | 129% | 106% | 100% | 84% | 89% | 92% | 174% | 162% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 112 | |||||||||||
| Inventory Days | 530 | |||||||||||
| Days Payable | 376 | |||||||||||
| Cash Conversion Cycle | 266 | |||||||||||
| Working Capital Days | -52 | |||||||||||
| ROCE % | -1% | -1% | -1% | -1% | -2% | -2% | -1% | -1% | -1% | -1% | -1% | -25% |
Insights
In beta| Mar 2016 | Sep 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Dec 2025 | |
|---|---|---|---|---|---|---|
| Top Customer Revenue Share % |
|
|||||
| Order Book (Total) INR Crore |
||||||
| EU Revenue Share % |
||||||
| Number of Global Customers Number |
||||||
| Number of Manufacturing Plants Number |
||||||
| Number of Scientists (R&D Capability) Number |
||||||
| USA Revenue Share % |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper publication of unaudited financial results of the company for the quarter ended June 30, 2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- Monitoring Agency Report for quarter ended June 30, 2026 confirms rights issue proceeds used as per objects.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor presentation for the quarter ended June 30, 2026
-
Financial Results For The Quarter Ended June 30, 2026
- Q1 FY26 unaudited results approved; revenue Rs 5,598.59 lakh, PAT Rs 673.53 lakh.
-
Board Meeting Outcome for The Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2026
- Board approved Q1 FY27 unaudited results on August 12, 2026; profit after tax was ₹673.53 lakh.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Overview:[1]
Innovassynth Technologies is a chemistry-focused CRDMO company engaged in research, development, and manufacturing across three key verticals — pharmaceutical intermediates, oligonucleotide building blocks, and specialty chemicals. It provides end-to-end services including custom synthesis, process development, scale-up, and commercial manufacturing for global life sciences and advanced materials customers. The company's oligonucleotide vertical focuses on nucleosides and amidites used in DNA/RNA therapeutics, while the specialty chemicals vertical serves applications in polyolefins, organometallic catalysts, and semiconductor materials. ITL uses chemistry capabilities, process innovation, and manufacturing expertise, to position itself as a long-term partner for global pharmaceutical and specialty chemical companies.